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A novel somatostatin analogue prevents early renal complica- glomerular hypertrophy, and accumulation of mesangial
tions in the nonobese diabetic mouse. extracellular matrix [2]. Obstruction of the glomerular
Background. PTR-3173 (S) is a novel somatostatin analogue capillary lumen and loss of glomerular filtration and func-that has been found to exert a prolonged inhibitory action on
tion are then observed [3]. Microalbuminuria followedthe growth hormone (GH)-insulin-like growth factor (IGF)-I
by proteinuria and worsening renal function are the clini-axis, but not on insulin secretion. We investigated the potential
effect of this agent on the development of markers of diabetic cal findings [4]. Insulin-like growth factor I (IGF-I) is a
nephropathy in the nonobese diabetic (NOD) mouse model of potent mitogenic polypeptide under growth hormone
insulin-dependent diabetes.
(GH) regulation [5]. Several studies have shown that theMethods. Female diabetic NOD mice treated with PTR-
GH-IGF system may play a significant role in diabetic3173 (DS group) or saline (D) and their control groups of
nonhyperglycemic age-matched littermates (C) and C mice and other nephropathies [6, 7]. Kidney tissue expresses
treated with PTR-3173 (CS) were sacrificed three weeks after receptors not only for IGF-I but also for GH [8]. Thus,
onset of diabetes. even though most of the biologic effects of GH are IGF-IResults. Serum GH was elevated in the D group, decreased
mediated, it may also act independently of IGF-I. Wein the DS group, and unchanged in the CS group. Serum IGF-I
have recently reported increased serum GH levels inwas significantly decreased in both the D and DS groups. Kid-
ney weight, glomerular volume, albuminuria, and creatinine nonobese diabetic (NOD) mice [9], a model of spontane-
clearance were increased in the D animals and showed a trend ous insulin-dependent diabetes. This is similar to the
toward normalization in the DS animals. Renal extractable
changes described in humans. Using the same model, weIGF-I protein and IGFBP1 mRNA were increased in the D
also observed a blunting effect by GH receptor antago-group and normalized in the DS group.
Conclusions. GH antagonism by PTR-3173 has a blunting nist on diabetic renal hypertrophy [10]. The molecular
effect on renal/glomerular hypertrophy, albuminuria, and glo- mechanism that mediates this effect is still unknown.
merular filtration rate (GFR) in diabetic NOD mice. This phe- Somatostatin, a 14-amino acid polypeptide, is a naturalnomenon is apparently associated with the prevention of renal
cyclic peptide inhibitor of pituitary, pancreatic, and gastro-IGF-I accumulation. Thus, modulation of GH effects may have
intestinal secretion [11]. The administration of octreotide,beneficial therapeutic implications in diabetic nephropathy.
a long-acting somatostatin analogue, to insulin-treated
patients with type 1 diabetes may impair antihypoglyce-
Nephropathy is one of the major complications of dia- mic counterregulatory mechanisms through suppression
betic angiopathy and one of the leading causes of end- of glucagon and GH responses [12]. However, the non-
stage renal failure and death in diabetic patients [1]. specific inhibitory effect of somatostatin on several other
The characteristic renal changes in early human diabetes hormones, including glucagon and insulin, in addition to
include an increase in glomerular filtration rate, renal and its expected effect on GH pituitary secretion, may have
a negative action in diabetic patients. Recently, Afargan
et al developed a novel somatostatin derivative, PTR-Key words: growth hormone, insulin-like growth factor-I, diabetes, renal
hypertrophy, PTR-3173, albuminuria. 3173, that has no inhibitory effects on glucagon and insu-
lin but exerts a major inhibition on pituitary GH secre-
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METHODS following the SC administration was calculated to be 100%.
A 1 mg/kg/day dose was selected, since 12 hours after drugAnimal experimentation
administration PTR-3173 significantly reduced, by 37%,
Twelve-week-old female NOD/Alt mice were pur- the plasma IGF-I levels in comparison to control levels.
chased from Jackson Laboratories (Bar Harbor, ME, In the DS and CS groups, subcutaneous injections of
USA). Animal breeding complied with the National In- PTR-3173 were administered at a dose of 1 mg/kg every
stitutes of Health Guide for the Care and Use of Labora- day, beginning on day one of hyperglycemia and until
tory Animals. The local institutional review committee the day of sacrifice, 21 days after diabetes onset. The
approved the study protocol. The cumulative incidence other two groups were injected at the same frequency and
of overt diabetes in these animals is over 70% by 100 days with the same volume of saline. Body weight was mea-
in females. Animals were housed in standard laboratory sured twice weekly. Urine was collected for 12 to 24 hours,
cages and fed normal mouse chow ad libitum with free using metabolic cages, on the day prior to sacrifice. A
access to an unlimited amount of tap water. The onset of proven standardized method of GH stimulation and se-
diabetes was determined by the appearance and persis- cretion was applied [14], wherein mice were anesthetized
tence of glycosuria, and these were checked twice a week with intraperitoneal (IP) pentobarbital (50 mg/kg), and
with chemstrips (Ketostix; Bayer-Ames, Tarrytown, NY, blood was drawn from the retrobulbar plexus at least
USA). When the urine glucose test was positive, tail five minutes after injection. The serum was separated
capillary glucose blood samples were examined with a and frozen at 20C for later measurement of glucose,
glucometer (Elite; Bayer Diagnostics, Puteaux Cedex, IGF-I, and GH. The right kidney was carefully removed
France). Diabetes was diagnosed when blood glucose and immediately frozen in liquid nitrogen and then at
levels were above the normal range for NOD mice (99% 70C. A coronal 2 mm slice from the midportion of
CI 3.0 to 9.9 mmol/L) on two consecutive days. The the left kidney was separated and fixed in a 4% paraform-
second day of persistent hyperglycemia was considered aldehyde solution for histomorphological assessment.
day 1 of diabetes. Only mice with elevated serum glucose
levels and no ketonuria were defined as diabetic. Dia- Immunoassays
betic mice can be maintained alive without insulin sup- Serum IGF-I. Serum IGF-I was measured by the func-
plementation for up to one month. The mice were di- tional separation method in which excess IGF-II blocks
vided into four groups (N  6 in each): (1) diabetic the interference of IGF binding proteins (IGFBPs)
mice (D), (2) diabetic mice treated with a somatostatin [15]. Serum (10 L) was diluted 1:100 in acidic buffer
analogue (DS; PTR-3173; Peptor Co., Rehovot, Israel), [0.02 mol/L NaH2PO4, 0.1 NaCl, 0.2% bovine serum albu-
(3) nondiabetic age-matched saline treated (C), or (4) min (BSA), 0.02% NaN3, 0.1% Triton X-100, pH 2.8] at
PTR-3173 treated controls (CS). PTR-3173 is a synthetic room temperature for one hour. Anti–IGF-I antiserum
seven-amino acid, hepta-backbone cyclic peptide that (Fujisawa Pharmaceutical Co, Osaka, Japan) was diluted
shares with native somatostatin the essential amino acid 1:70,000 in assay buffer [0.1 mol/L phosphate-buffered
sequence (Phe-aromatic ring-Trp-Lys-Thr-Phe) that is saline (PBS), 0.2% BSA, 0.02% NaN3, 0.1% Triton
responsible for efficacy. This novel compound has been X-100, pH 7.8]. Thereafter, 100 L of samples and re-
recently described [13]. Briefly, the metabolic stability combinant human IGF-I (rhIGF-I) standards (Fujisawa
of PTR-3173 was comparable to that of the previously Pharmaceutical Co.) were incubated with 50 L IGF-II
described drug octreotide. Both compounds showed a (100 ng/mL; PeproTech Inc., Rocky Hill, NJ, USA),
higher biostability than the native hormone somato- 400 L antiserum, and 125I IGF-I (25,000 cpm/50 L)
statin. PTR-3173 and octreotide were equipotent inhibi- at 4C for 20 hours. Bound and free antibodies were
tors of GH release under the same experimental condi- separated by incubation with a pre-precipitated suspen-
tions; however, PTR-3173 significantly reduced glucagon sion of an anti-rabbit IgG (Sigma, St. Louis, MO, USA)-
and insulin release with less potency than the drug oc- normal rabbit serum mix (1%:0.1%) in 5% polyethylene
treotide. The pharmacokinetics of PTR-3173 following glycol (1 mL). IGF-II (5 ng/tube) completely reversed
an intravenous (IV) bolus administration was similar to the interference of human recombinant IGFBP-3 (5 ng/
that of octreotide. The same volume of distribution and tube; Upstate Biotechnology, Lake Placid, NY, USA).
clearance was observed for both drugs. A considerable The sensitivity was 0.02 ng IGF-I/tube; the intra-assay
pharmacokinetic advantage was found with PTR-3173, coefficients of variation for sera with IGF-I levels 80,
following subcutaneous (SC) administration. The elimi- 212, and 412 ng/mL were 8.9, 2.9, and 9.6%, respectively.
nation of PTR-3173 from the systemic circulation in the All sera were run in the same assay.
postabsorptive phase was significantly slower than in the Serum growth hormone. Serum GH was measured by
case of an IV bolus administration. The elimination half- radioimmunoassay [16]. Mouse sera were diluted 1:4 or
life was approximately 170 minutes, indicating flip-flop 1:20 in assay buffer [0.01 mol/L PBS, 0.02% NaN3, 0.33%
ethylenediaminetetraacetic acid (EDTA), 0.5% BSA,kinetics following SC administration. The bioavailability
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pH 7.5]; anti-rat GH antiserum (monkey; donated by (tuft omitting the proximal tubular tissue within the Bow-
man capsule), and VG was calculated as {VG  (/) Dr. A.F. Parlow) was diluted 1:125,000 in normal mon-
key serum (1% in assay buffer; Harlan Labs, Rehovot, (AG)3/2}, where   1.38 is the shape coefficient for
spheres (the idealized shape of glomeruli) and   1.1Israel). Mouse GH (AFP-10783B; Dr. A.F. Parlow) was
used for iodinization and standards. Samples and stan- is a size distribution coefficient.
Urine albumin excretion. The urine samples weredards (100 L), 125I mGH (200 L), and antiserum
(100 L) were incubated for 22 hours at room tempera- stored at 20C until assayed. The urinary albumin con-
centration in the urine samples collected prior to sacrificeture. Bound and free antibodies were separated by incu-
bation with anti-monkey IgG-diluted 4:6 (100 L; ICN was determined by a modified enzyme-linked immuno-
sorbent assay (ELISA). Ninety-six–well immunoplatesPharmaceuticals Inc., Aurora, OH, USA) and the addi-
tion of ice-cold polyethylene glycol 5% (1 mL) at 4C were coated with goat anti-mouse albumin (Bethyl Labs,
Montgomery, TX, USA), diluted with 0.1 mol/L carbon-for two hours. The sensitivity of the method was 0.04 ng
mGH/tube; the coefficients of variation for sera 13.9 and ate buffer (pH 9.6), and incubated overnight at 4C. The
plates were washed four times with 0.01 mol/L PBS (pH201.1 ng/mL were 13.6 and 5.9%, respectively. All sera
were run in the same assay. 7.4) and 0.05% Tween-20, and were incubated for one
hour with 5% milk to avoid nonspecific binding. Stan-mRNA studies. Total RNA was prepared from frozen
tissues by Tri reagent (Molecular Research Center, Cin- dard dilutions of mouse albumin (Fraction V; ICN Phar-
maceuticals Inc., Cleveland, OH, USA) or test samplescinnati, OH, USA) and quantified by absorbency at
260 nm. The integrity of the RNA was assessed by visual diluted with PBS were added to the wells and incubated
for two hours at 37C. The plates were washed four timesinspection of the ethidium bromide-stained 28S and 18S
RNA bands, after electrophoresis through 1.25%/2.2 mol/L and then incubated for one hour with horseradish peroxi-
dase-conjugated goat anti-mouse albumin (Bethyl Labs).formaldehyde gels. For Northern blot analysis, 40 g
of total RNA were electrophoresed on 1.3% agarose/ Transmethyl benzidine (TMB)-substrate solution (Dako
Corp., Carpenteria, CA, USA) was then added to each2.2 mol/L formaldehyde gels in 3-morpholinopropanes-
ulfonic acid buffer. The RNA was then transferred onto well, and the absorbency was read at 450 nm with a micro-
titer plate reader and compared with a standard curve.MagnaGraph (MSI, Westboro, MA, USA) nylon mem-
branes and cross-linked to the membrane with an ultravi- Intra-assay and interassay coefficients of variation were
less than 5 and 10%, respectively. However, in the pres-olet cross-linker (Hoefer Scientific Instruments, San
Francisco, CA, USA). The rat IGFBP-1 probe (a gift from ent study, all samples were run in one assay, in duplicates.
L. Mathews) was radiolabeled with (32P)dCTP 3000 Ci/
Other assaysmmol (Amersham, Buckinghamshire, UK) by a random
DNA-labeling kit (Boehringer Mannheim, GmbH, Mann- Blood glucose levels were determined by either the
Elite glucometer (as previously mentioned) or by theheim, Germany).
RNA hybridization was performed in a hybridization glucose oxidase method (upon sacrifice) [19].
Urine creatinine values were assessed simultaneouslyoven (Micro-4; Hybaid Ltd., Teddington, UK) at 65C
for 20 hours using a hybridization solution [0.2 mmol/L to calculate albumin/creatinine ratios and creatinine
clearances as an indicator of glomerular filtration rate.Na2HPO4, pH 7.2, 7% (vol/vol) sodium dodecyl sulfate,
1% (SDS; wt/vol) BSA, and 1 mmol/L EDTA]. The wash-
Statisticsings were done in 0.4  standard saline citrate (SSC) and
0.1% SDS at 65C. Gels were exposed to Kodak X-Omat One-way analysis of variance was used to evaluate
differences between groups for multiple comparisons. AAR film (Eastern Kodak, Rochester, NY, USA) at70C
with two intensifying screens. The autoradiograms were P value of less than 0.05 was considered as significant.
Means are given as  SEM.quantified with a phosphorimager (Imagequant; Molecu-
lar Dynamics, Sunnyvale, CA, USA). Each experiment
was repeated twice.
RESULTS
Estimation of glomerular volume. A 2 mm thick, hori-
Body weight and metabolic parameterszontally cut slice from the middle of the right kidney
(containing the papilla) was fixed in 4% paraformalde- Diabetic and DS mice showed a slight decrease in
body weight (96  3% of C in both groups) prior tohyde and embedded in Technovit. Sections of 2m thick-
ness were cut on a rotation microtome and stained with sacrifice compared with the C and CS groups. The weight
of the CS group was not different from the weight ofperiodic acid-Schiff (PAS) and hematoxylin. The mean
glomerular tuft volume (VG) was determined from the the C group. No animal developed ketonuria during the
experimental protocol. Serum glucose levels at sacrificemean glomerular cross-sectional area (AG) by light mi-
croscopy, as previously described [17, 18]. AG was deter- were significantly elevated in both diabetic groups (495
131 and 526  124 mg% in D and DS, respectively, vs.mined as the average area of a total of 40 to 80 glomeruli
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Fig. 1. Mean serum growth hormone (GH; ng/mL) (A) and insulin-
like growth factor-I (IGF-I; ng/mL) (B) levels on day 21 in the control
(C), PTR-3173–treated C (CS), untreated diabetic (D), and PTR-3173–
treated diabetic (DS) groups. Values are mean  SEM; N  6 in each
group. *P 	 0.05 vs. C.
75.6  17 mg% in C and 73.6  10 mg% in CS). There
was no significant difference in blood glucose levels be-
tween the two diabetic groups.
Serum GH and IGF-I
Serum GH levels were markedly elevated in the D
group (233  92 ng/mL) compared with the C and CS
Fig. 2. Mean absolute kidney weight (mg) (A), glomerular volumegroups (30  11 and 38  15 ng/mL, respectively, (105 m3) (B) and kidney-extractable IGF-I protein (ng/g tissue) (C )
P 	 0.01). PTR-3173 treatment prevented the rise in on day 21 in the control untreated (C), PTR-3173–treated C (CS),
untreated diabetic (D) and PTR-3173–treated diabetic (DS) groups.serum GH levels in the DS group. However, serum GH
Values are mean  SEM; N  6 in each group. *P 	 0.05 vs. C.levels in the DS group were still significantly different
from control (85  15 ng/mL vs. 30  11, P 	 0.05
vs. C, but P  NS vs. D; Fig. 1). An opposite trend
was observed for serum IGF-I, which was significantly
decreased in both diabetic groups compared with con- by a mean of 37  5% over the nondiabetic controls
trols (180 32 and 242  42 ng/mL in D and DS respec- (199  7 vs. 145  3 mg, P 	 0.05). Kidney weight
tively vs. 429  17 and 421  19 ng/mL in C and CS, increased less in the DS group (178  7 mg) comparedrespectively, P 	 0.01; Fig. 1). There was no significant
with the D animals. Glomerular volume increased sig-difference in the change in serum IGF-I levels between
nificantly in the D group (4.5  0.3  105 in the D groupthe D and DS groups.
vs. 3.4  0.2  105 m3 in the C group, P 	 0.05).
Kidney weight and glomerular volume In the DS group, however, an intermediate value of
glomerular volume (4.1  0.2  105 m3) between theFigure 2 shows the kidney weights for the four groups
after 21 days. Kidney weight increased in the D group C and D groups was observed.
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Fig. 3. (A) Northern blot analysis of kidney IGFBP-1 mRNA, using
40 g total RNA, on day 21 in the control (C), PTR-3173–treated
C (CS), untreated diabetic (D), and PTR-3173–treated diabetic (DS)
groups. The 1.6 kb bands corresponding to the IGFBP-1 transcript are Fig. 4. Urinary albumin excretion (g/24 h) (A) and creatinine clear-
shown in the upper lane. The film was exposed for 48 hours at 70C ance (L/min) (B) on day 21 in the control untreated (C), PTR-3173–
with two intensifying screens. The ethidium bromide staining of the treated C (CS), untreated diabetic (D), and PTR-3173–treated diabetic
18S and 28S ribosomal RNA of the samples prior to their transfer to (DS) groups. Values are mean  SEM; N  7 to 10 in each group.
the membrane appears in the lower lane. (B) Quantitation of kidney *P 	 0.05 vs. C; †P 	 0.05 vs. D.
IGFBP-1 mRNA levels from the autoradiograph shown in Figure 4A,
using a phosphorimager. The data are expressed as the percentage of
control. *P 	 0.05 vs. C and DS.
comparison to the D group (13.3  3.3 g/24 hours, P 	
0.05 vs. D; Fig.4A).
Kidney IGF-I and IGFBP-1 Creatinine clearance
Kidney IGF-I increased in the D group by 197  13% Creatinine clearance (CCr) as assessed from the 24-
of C (Fig. 2); the increase was less prominent in the DS hour urine collection was markedly increased in the D
animals (108  11 ng/g or 166  11% of C). Treatment animals compared to both treated and untreated controls
with PTR-3173 did not affect kidney IGF-I levels in (220  14 L/min in D vs. 94  13 and 95  10 L/min
the nondiabetic animals. Kidney IGFBP-1 mRNA levels in C and CS, respectively; P	 0.01). CCr in the DS group
was significantly lower than in the D group (133 15L/increased in the D group to 1170 548% of C (P	 0.01)
min, P 	 0.01 vs. D; Fig. 4B).and significantly decreased in the DS group (140  24%
of C, P  NS vs. C and CS; Fig. 3).
DISCUSSION
Urinary albumin excretion
This study shows that the exogenous administration
The urinary albumin excretion (UAE) values were de- of PTR-3173 in mice with spontaneous type 1 diabetes
rived from 24-hour urine collection prior to sacrifice in has an effect on markers of early diabetic nephropathy
the four experimental groups. The untreated diabetic (renal hypertrophy, glomerulomegaly, albuminuria, and
animals exhibited a marked elevation in UAE to 20.9  hyperfiltration).
2.7 compared with 4.2  0.8 g/24 hours in the nondia- Growth hormone and IGF-I may play a pathogenic
role in diabetic as well as other nephropathies. Poorlybetic mice. The UAE in the DS group was decreased in
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controlled diabetes in humans is characterized by GH hyperglycemia/insulinopenia induce a decrease in serum
IGF-I, which in turn induces GH hypersecretion [21],hypersecretion [20, 21]. Transgenic mice for the bovine
GH gene show a disproportionate increase in glomerular making optimal metabolic control more difficult to
achieve. Accordingly, a potential negative effect of GHvolume followed by severe glomerulosclerosis, uremia,
and death [22]. In addition, kidneys of transgenic diabetic antagonists in diabetes could be a further lowering of
circulating IGF-I, which may contribute to insulin resis-mice that express GH antagonists (bGH-G119R and
rhGH-G120R) had less glomerular hypertrophy and tance. However, with the dose of PTR-3173 used in the
present study, normalizing serum GH had no effects ondamage, no proteinuria, and no increase in glomerular
1
type IV collagen mRNA levels compared with kidneys of metabolic control.
Our data support findings in previous reports sug-transgenic diabetic mice that expressed wild-type bGH
[23–25]. However, mice transgenic to GH antagonist may gesting that renal hypertrophy in type I diabetes is medi-
ated by the increase in renal IGF-I content, despite thebe a priori less susceptible to diabetic renal changes
owing to an inborn effect of GHR blockade and low decrease in circulating IGF-I levels [30]. In our current
study, the rise in kidney IGF-I protein in untreated dia-circulating IGF-I levels (resulting in a dwarf phenotype)
before the induction of diabetes. In contrast, our data betes was blunted by PTR-3173 treatment. This was asso-
ciated with a marked decrease in renal IGFBP1 mRNAare based on a model of spontaneously acquired insulin-
dependent diabetes [26, 27], which closely resembles hu- levels. Kidney IGF-I increased significantly in the D
group. This increase was less prominent in the DS ani-man disease [28]. Like humans, NOD mice develop pro-
teinuria and glomerular lesions, including an increase in mals (Fig. 2). Although this last observation showed no
statistical significance versus control animals, there wasglomerular surface area and in mesangial sclerosis [29].
We have previously described an increase in circulating a trend for the IGF-I protein to rise.
This study demonstrates no toxic effects of PTR-3173GH levels [9] associated with a persistent increase in
kidney-extractable IGF-I levels and renal hypertrophy treatment in the diabetic animals, nor any effect on se-
rum GH or IGF-I in the nondiabetic ones. In addition,up to four weeks after diabetes onset in NOD mice [30],
imitating human insulin-dependent diabetes mellitus. there was no worsening in the degree of hyperglycemia
in the DS animals in spite of the potential inhibitingWe also described a persistent increase in kidney extract-
able IGF-I levels in association with renal hypertrophy effect of somatostatin on insulin secretion. These charac-
teristics make PTR-3173 a good therapeutic candidate inin NOD mice up to four weeks after diabetes onset.
Renal hypertrophy and albuminuria in diabetic rats humans. Indeed, octreotide, lanreotide, and vapreotide
have all been somatostatin analogues approved for hu-can be prevented by the administration of long-acting
somatostatin analogues (for example, octreotide and lan- man use and have been shown to be clinically effective
in various endocrine and gastrointestinal anomalies. Inreotide), which are believed to be nonspecific inhibitors
of the GH/IGF axis [31, 32]. Somatulin (another long- one clinical study, 12-week treatment with octreotide
was found to decrease glomerular hyperfiltration, as wellacting somatostatin analogue) treatment for three months
in patients with type 1 diabetes lowered glomerular fil- as total kidney volume in a small group of diabetic pa-
tients [36]. Overall, these studies, although inconclusive,tration rate (GFR) and effective renal plasma flow com-
pared with placebo. IGF-I concentrations were decreased have at least shown that these long-acting somatostatin
analogues have a satisfactory safety profile, even whenin all somatulin-treated patients, and GH secretion tended
to increase only in the placebo group [33]. However, as given for long periods and in spite of their nonspecific
effect on other hormones.somatostatin has potent inhibitory effects on the secretion
of a large number of other hormones, including insulin, The novel somatostatin analogue used in this study
(PTR-3173) showed a significant specificity in GH inhibi-glucagon, gastrin, cholecystokinin, and other mediators
secreted by the pituitary, pancreas, and the gastrointesti- tion. Somatostatin’s biological functions are mediated
via high affinity, nonselective somatostatin binding tonal tract [34], it may adversely affect the metabolic bal-
ance. Therefore, a more specific antagonist of GH secre- specific cell surface receptors, namely, SSTR-1, -2A, -2B,
-3, -4, and -5, which are encoded by five genes and be-tion is needed to prevent diabetic complications.
In poorly controlled insulin-dependent diabetes in hu- long to the G-protein–coupled receptor family [37]. Ac-
cording to in vitro studies, PTR-3173 is bound withmans (and in mice, as shown in this study), hyperglyce-
mia and insulinopenia do not suppress GH secretion. nmol/L affinity to three of the six identified human SS
receptors (SSTR): SSTR-2, SSTR-4, and SSTR-5. So-Serum IGF-I levels are reduced in hyperglycemic dia-
betic subjects in spite of elevated GH levels. This phe- matostatin inhibition of glucagon release in mouse islets
is primarily mediated via SSTR-2, whereas insulin secre-nomenon has been explained by the inhibition of hepatic
IGF-I synthesis due to a decrease in hepatic GHR ex- tion is regulated primarily via SSTR-5 [38]. These recep-
tors have variable tissue distribution and metabolic ef-pression and binding [35]. The metabolic consequences
of these alterations are a “vicious cycle” wherein the fects, including kidney tissue, where they localize in a
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2. Wiseman MJ, Mangili R, Alberetto M, et al: Glomerular responsetubular distribution [39]. In humans, somatostatin recep-
mechanisms to glycemic changes in insulin-dependent diabetics.
tors revealed binding over cortical and medullary areas. Kidney Int 31:1012–1018, 1987
3. Steffes MW, Østerby R, Chavers B, Mauer SM: MesangialIn the cortex, the receptors were located in the proximal
expansion as a central mechanism for loss of kidney function intubules but not in the glomeruli. In the medulla, the
diabetic patients. Diabetes 38:1077–1081, 1989
receptors were identified in high density in medullary 4. Viberti GC: Early function and morphological changes in diabetic
nephropathy. Clin Nephrol 12:47–53, 1979vasa recta [40]. RNA blotting studies show that human
5. LeRoith D, Adamo M, Werner H, Roberts CT Jr: Insulin-likeSSTR-2 are expressed at the highest levels in cerebrum
growth factors, their binding proteins and receptors as growth
and kidney [41]. Somatostatin analogues decrease opos- regulators in normal physiology and pathological states. Trends
Endocrinol Metab 2:134–141, 1991sum kidney (OK) tubular cell proliferation in a dose-
6. Landau D, Chin E, Bondy C, et al: Expression of insulin-likedependent manner [42]. Moreover, receptors with struc-
growth factor binding proteins in the rat kidney: Effects of long-
tural and biological specificities for somatostatin are term diabetes. Endocrinology 136:1835–1842, 1995
7. Flyvbjerg A: Role of growth hormone, insulin-like growth factorspresent in the adrenal glomerulosa zone [43], where they
(IGFs) and IGF-binding proteins in the renal complications ofserve as regulatory sites for somatostatin inhibition of
diabetes. Kidney Int 51(Suppl 60):S12–S19, 1997
the action of angiotensin II on aldosterone production 8. Chin E, Zhou J, Bondy C: Renal growth hormone gene expression:
Relationship to renal insulin-like growth factor system. Endocri-in the adrenal glomerulosa cells. Somatostatin prevented
nology 131:3061–3066, 1992the reduction in mesangial cell planar surface area in-
9. Landau D, Segev Y, Eshet R, et al: Changes in the growth hor-
duced by angiotensin II in a dose-dependent manner. mone-IGF-I axis in nonobese diabetic mice. Int J Exp Diab Res
1:9–18, 2000This effect was not inhibited by the use of other vasore-
10. Segev Y, Landau D, Rasch R, et al: Growth hormone receptorlaxing agents [44]. Thus, a compound with differential
antagonism prevents early renal changes in the non-obese diabetic
effects on the different SSTRs may have a more specific (NOD) mouse. J Am Soc Nephrol 10:2374–2381, 1999
11. Reichlin S: Somatostatin. N Engl J Med 309:1495–1501, 1983action to the kidney. In hormone secretion studies in
12. Lunetta M, Di Mauro M, Le Moli R, Nicoletti F: Effect ofrats, the median effective dose values of PTR-3173 for
octreotide on growth hormone, IGF-I, IGFBP-3, glucagon, cortisol
GH release were approximately 1,000-fold and10,000- and epinephrine response to insulin-induced hypoglycaemia in in-
sulin-dependent diabetic patients. Diabetes Metab 23:524–527, 1997fold lower than those affecting glucagon and insulin re-
13. Afargan M, Tiensuu-Janson E, Gelerman G, et al: Novel longlease, respectively [13]. Therefore, the use of PTR-3173
acting somatostatin analog with endocrine selectivity: Potent sup-
in human diabetes may offer additional advantages over pression of growth hormone but not of insulin. Endocrinology
142:477–486, 2001the current somatostatin analogues.
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